The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975

2.

Researchers Challenge USPSTF's Lung Cancer Screening Criteria

3.

Prostate cancer Q&A: Improving detection and reducing overtreatment

4.

Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted

5.

How 7,000 steps a day could help reduce your risk of cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot